NervGen Pharma (NGEN) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NervGen Pharma (NGEN) has outperformed PepGen (PEPG) over the past year, losing 48.2% versus a loss of 51.1%. NervGen Pharma is the larger company by market cap ($186.6 million vs $182.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGEN | PEPG |
|---|---|---|
| Share price | $1.74 | $2.64 |
| Market cap | $186.55M | $182.61M |
| 1-day change | -0.86% | +10.92% |
| YTD return | -68.75% | -63.44% |
| 1-year return | -48.18% | -51.13% |
| 5-year return | -7.41% | — |
| EPS (TTM) | $-0.57 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.30 | $7.80 |
| 52-week low | $1.58 | $1.31 |
| Distance from 52-week high | -72.46% | -66.15% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +476.37% | +285.98% |
| Average volume | 565.19K | 946.80K |
| Shares outstanding | 107.52M | 69.17M |
| Employees | 9 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
NGEN vs PEPG FAQ
Which is bigger, NervGen Pharma or PepGen?
NervGen Pharma (NGEN) is larger, with a market capitalization of $186.55M compared with $182.61M for PepGen (PEPG).
Which stock has performed better over the past year, NGEN or PEPG?
NGEN returned -48.18% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are NervGen Pharma and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.